Skip to content

Study · Randomized controlled trial · n = 273 · 2021

10 results

Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge.

Pasquel FJ, Urrutia MA, Cardona S, Coronado KWZ, Albury B, Perez-Guzman MC, Galindo RJ, Chaudhuri A, Iacobellis G, Palacios J, Farias JM, Gomez P and 7 more

Show all authors

Anzola I, Vellanki P, Fayfman M, Davis GM, Migdal AL, Peng L, Umpierrez GE

Diabetes, obesity & metabolism31 Mar 2021Cited by 19 (Europe PMC)

PMID33591621 (opens in a new tab)PMCIDPMC8571803 (opens in a new tab)DOI10.1111/dom.14347 (opens in a new tab)PepBankPUB-33591621
Source linkPubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with uncontrolled type 2 diabetes at hospital discharge, the HbA1c difference between liraglutide and insulin glargine at 12 weeks was -0.28%, with a confidence interval that included zero.

    In plain wordsIn adults with type 2 diabetes leaving hospital, liraglutide and insulin glargine did not clearly differ in HbA1c at 12 weeks.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c difference at 12 weeks
    Study

    n = 273

    Comparator
    Insulin glargine
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c difference
    −0.28%
    liraglutide vs insulin glargine, 12 weeks

    Source sentences

    Summary
    The between-group difference in HbA1c at 12 weeks and 26 weeks was -0.28% (95% CI -0.64, 0.09)
    1 context sentence
    Summary · context
    A total of 273 patients with glycated haemoglobin (HbA1c) 7%-10% (53-86 mol/mol) were randomized to liraglutide (n = 136) or insulin glargine (n = 137) at hospital discharge.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with uncontrolled type 2 diabetes at hospital discharge, HbA1c at 26 weeks was 0.55% lower with liraglutide than with insulin glargine.

    In plain wordsIn adults with type 2 diabetes leaving hospital, liraglutide lowered HbA1c more than insulin glargine at 26 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c difference at 26 weeks
    Study

    n = 273

    Comparator
    Insulin glargine
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c difference
    −0.55%
    liraglutide vs insulin glargine, 26 weeks

    Source sentences

    Summary
    The between-group difference in HbA1c at 12 weeks and 26 weeks was -0.28% (95% CI -0.64, 0.09), and at 26 weeks it was -0.55%, (95% CI -1.01, -0.09) in favour of liraglutide.
    1 context sentence
    Summary · context
    A total of 273 patients with glycated haemoglobin (HbA1c) 7%-10% (53-86 mol/mol) were randomized to liraglutide (n = 136) or insulin glargine (n = 137) at hospital discharge.
  3. 03HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes after hospital discharge, hypoglycaemia below 3.9 mmol/L was less frequent with liraglutide than with insulin glargine (13% versus 23%).

    In plain wordsIn adults with type 2 diabetes leaving hospital, mild low blood sugar happened less often with liraglutide than with insulin glargine.

    Peptide
    Liraglutide
    Outcome
    DecreaseHypoglycaemia below 3.9 mmol/L
    Study

    n = 273

    Comparator
    Insulin glargine
    Analysis
    Secondary
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    frequency of hypoglycaemia <3.9 mmol/L
    13%
    liraglutide
    frequency of hypoglycaemia <3.9 mmol/L
    23%
    insulin glargine

    Source sentences

    Summary
    Liraglutide treatment resulted in a lower frequency of hypoglycaemia <3.9 mmol/L (13% vs 23%; P = 0.04)
    1 context sentence
    Summary · context
    A total of 273 patients with glycated haemoglobin (HbA1c) 7%-10% (53-86 mol/mol) were randomized to liraglutide (n = 136) or insulin glargine (n = 137) at hospital discharge.
  4. 04HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes after hospital discharge, the rate of clinically significant hypoglycaemia below 3.0 mmol/L did not differ between liraglutide and insulin glargine.

    In plain wordsIn adults with type 2 diabetes leaving hospital, serious low blood sugar happened about as often with liraglutide as with insulin glargine.

    Peptide
    Liraglutide
    Outcome
    No significant changeClinically significant hypoglycaemia below 3.0 mmol/L
    Study

    n = 273

    Comparator
    Insulin glargine
    Analysis
    Secondary
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but there was no difference in the rate of clinically significant hypoglycaemia <3.0 mmol/L.
    1 context sentence
    Summary · context
    A total of 273 patients with glycated haemoglobin (HbA1c) 7%-10% (53-86 mol/mol) were randomized to liraglutide (n = 136) or insulin glargine (n = 137) at hospital discharge.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes after hospital discharge, liraglutide gave greater weight loss than insulin glargine at 26 weeks (-4.7 kg versus -0.6 kg).

    In plain wordsIn adults with type 2 diabetes leaving hospital, people on liraglutide lost more weight than people on insulin glargine.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change at 26 weeks
    Study

    n = 273

    Comparator
    Insulin glargine
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    weight change
    −4.7 kg
    liraglutide, 26 weeks
    weight change
    −0.6 kg
    insulin glargine, 26 weeks

    Source sentences

    Summary
    Compared to insulin glargine, liraglutide treatment was associated with greater weight loss at 26 weeks (-4.7 ± 7.7 kg vs -0.6 ± 11.5 kg; P < 0.001
    1 context sentence
    Summary · context
    A total of 273 patients with glycated haemoglobin (HbA1c) 7%-10% (53-86 mol/mol) were randomized to liraglutide (n = 136) or insulin glargine (n = 137) at hospital discharge.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes after hospital discharge, 48% reached HbA1c below 7% without hypoglycaemia at 12 weeks with liraglutide versus 33% with insulin glargine (P = 0.05).

    In plain wordsIn adults with type 2 diabetes leaving hospital, more people on liraglutide reached the blood sugar target without low blood sugar at 12 weeks.

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c below 7% without hypoglycaemia at 12 weeks
    Study

    n = 273

    Comparator
    Insulin glargine
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    proportion with HbA1c <7% without hypoglycaemia
    48%
    liraglutide, 12 weeks
    proportion with HbA1c <7% without hypoglycaemia
    33%
    insulin glargine, 12 weeks

    Source sentences

    Summary
    the proportion of patients with HbA1c <7% (53 mmol/mol) without hypoglycaemia was 48% versus 33% (P = 0.05) at 12 weeks and 45% versus 33% (P = 0.14) at 26 weeks in liraglutide versus insulin glargine.
    1 context sentence
    Summary · context
    A total of 273 patients with glycated haemoglobin (HbA1c) 7%-10% (53-86 mol/mol) were randomized to liraglutide (n = 136) or insulin glargine (n = 137) at hospital discharge.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes after hospital discharge, the proportion reaching HbA1c below 7% without hypoglycaemia at 26 weeks did not differ significantly between liraglutide and insulin glargine (45% versus 33%).

    In plain wordsIn adults with type 2 diabetes leaving hospital, reaching the target without lows at 26 weeks was not clearly different, liraglutide versus insulin glargine.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c below 7% without hypoglycaemia at 26 weeks
    Study

    n = 273

    Comparator
    Insulin glargine
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    proportion with HbA1c <7% without hypoglycaemia
    45%
    liraglutide, 26 weeks
    proportion with HbA1c <7% without hypoglycaemia
    33%
    insulin glargine, 26 weeks

    Source sentences

    Summary
    the proportion of patients with HbA1c <7% (53 mmol/mol) without hypoglycaemia was 48% versus 33% (P = 0.05) at 12 weeks and 45% versus 33% (P = 0.14) at 26 weeks in liraglutide versus insulin glargine.
    1 context sentence
    Summary · context
    A total of 273 patients with glycated haemoglobin (HbA1c) 7%-10% (53-86 mol/mol) were randomized to liraglutide (n = 136) or insulin glargine (n = 137) at hospital discharge.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes after hospital discharge, more people reached HbA1c below 7% without hypoglycaemia and without weight gain at 12 weeks with liraglutide than with insulin glargine (41% versus 24%).

    In plain wordsIn adults with type 2 diabetes leaving hospital, more people on liraglutide reached the target with no lows and no weight gain at 12 weeks.

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c below 7% without hypoglycaemia and without weight gain at 12 weeks
    Study

    n = 273

    Comparator
    Insulin glargine
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    proportion with HbA1c <7% without hypoglycaemia and weight gain
    41%
    liraglutide, 12 weeks
    proportion with HbA1c <7% without hypoglycaemia and weight gain
    24%
    insulin glargine, 12 weeks

    Source sentences

    Summary
    The proportion of patients with HbA1c <7% (53 mmol/mol) without hypoglycaemia and no weight gain was higher with liraglutide at 12 (41% vs 24%, P = 0.005) and 26 weeks (39% vs 22%; P = 0.014).
    1 context sentence
    Summary · context
    A total of 273 patients with glycated haemoglobin (HbA1c) 7%-10% (53-86 mol/mol) were randomized to liraglutide (n = 136) or insulin glargine (n = 137) at hospital discharge.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes after hospital discharge, more people reached HbA1c below 7% without hypoglycaemia and without weight gain at 26 weeks with liraglutide than with insulin glargine (39% versus 22%).

    In plain wordsIn adults with type 2 diabetes leaving hospital, more people on liraglutide reached the target with no lows and no weight gain at 26 weeks.

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c below 7% without hypoglycaemia and without weight gain at 26 weeks
    Study

    n = 273

    Comparator
    Insulin glargine
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    proportion with HbA1c <7% without hypoglycaemia and weight gain
    39%
    liraglutide, 26 weeks
    proportion with HbA1c <7% without hypoglycaemia and weight gain
    22%
    insulin glargine, 26 weeks

    Source sentences

    Summary
    The proportion of patients with HbA1c <7% (53 mmol/mol) without hypoglycaemia and no weight gain was higher with liraglutide at 12 (41% vs 24%, P = 0.005) and 26 weeks (39% vs 22%; P = 0.014).
    1 context sentence
    Summary · context
    A total of 273 patients with glycated haemoglobin (HbA1c) 7%-10% (53-86 mol/mol) were randomized to liraglutide (n = 136) or insulin glargine (n = 137) at hospital discharge.
  10. 10HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes after hospital discharge, gastrointestinal adverse events were more frequent with liraglutide than with insulin glargine.

    In plain wordsIn adults with type 2 diabetes leaving hospital, stomach and bowel side effects happened more often with liraglutide than with insulin glargine.

    Peptide
    Liraglutide
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n = 273

    Comparator
    Insulin glargine
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The incidence of gastrointestinal adverse events was higher with liraglutide than with insulin glargine (P < 0.001).
    1 context sentence
    Summary · context
    A total of 273 patients with glycated haemoglobin (HbA1c) 7%-10% (53-86 mol/mol) were randomized to liraglutide (n = 136) or insulin glargine (n = 137) at hospital discharge.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.